John Efthimiou, MD, FRCP 

Board certified pulmonologist trained in London and Oxford respiratory centers of excellence. He brings 30+ years of global, strategic and operational drug development experience in large and small pharma and biotech companies. Extensive history of successful clinical development (200+ Phase 1-III studies) and regulatory approvals, including novel therapies for CF, NCFB, COPD, asthma, CRS and IPF, and in infectious, inflammatory and rare diseases.